glp-1/fgf21 agonist boehringer Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Novel Therapies for Cardiometabolic Disease:

Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice

Y., Gaspar, S., Deroisy, R., Zegels, B

To avoid confounding, etiologies of AP including alcohol-induced, trauma, biliary, class Ia drug-induced, hypertriglyceridemia, and postendoscopic retrograde cholangiopancreatography were excluded from both cohorts

3 Pharmacologic Treatment As previously mentioned, when glycemic control and dietary changes do not attenuate symptoms, prokinetic agents may be prescribed ( TABLE 3 )

Action of glucose-dependent insulinotropic polypeptide (GIP) in humans

Rather than a reason to panic, this finding should be seen as a reminder: no drug is without risk, but knowledge empowers both patients and providers to act quickly if needed